Orexin-2 Receptor Antagonism as a Target for Mitigating Fentanyl-Induced Sleep Disruption in C57BL/6J Mice
Date Issued
August 2026
Author(s)
Cooper, Natania Willow
The University of Tennessee
Advisor(s)
Helen Baghdoyan
Additional Advisor(s)
Ralph Lydic
Billy Lau
Abstract
Orexin is a wakefulness promoting peptide that exerts its excitatory effects by activating two G protein-coupled receptors. Dual orexin receptor antagonists (DORAs) are prescribed for the treatment of insomnia. The orexin-2 receptor (OX2R) antagonist JNJ-10397049 has 10-fold higher potency for increasing non-rapid eye movement (NREM) sleep in the rat than the DORA suvorexant. Opioids cause sleep disruption, exacerbating pain and producing a range of negative health consequences. Using C57BL/6J (B6) mice, the present study tested the hypothesis that blocking OX2Rs mitigates fentanyl-induced sleep disruption. Mice (n=10) were implanted with telemeters for recording the cortical electroencephalogram (EEG) and neck muscle activity to quantify states of wakefulness, rapid eye movement (REM) sleep, and NREM sleep. Recordings (4 h) began within 90 minutes of light onset and within 15 minutes of light offset. The OX2R antagonist and its vehicle (15% DMSO in deionized water) were compared during both light and dark periods. When administered alone, the OX2R antagonist JNJ-10397049 (10 mg/kg, IP) had relatively few effects on sleep states, which were significantly delaying the onset of REM sleep during the subjective night (light period) and altering transitions out of REM sleep into wakefulness and NREM sleep. Fentanyl (0.3 mg/kg, SC) eliminated NREM and REM sleep in 60% and 100% of subjects, respectively, during the subjective day (dark period). With the OX2R antagonist pre-treatment, NREM sleep was returned in 90% of subjects. The OX2R antagonist partially attenuated fentanyl-induced sleep disruption during the subjective day by significantly (P < 0.05) reducing the time to enter NREM sleep after fentanyl administration and increasing the frequency and duration of NREM episodes. Additionally, fentanyl caused a significant decrease in waking EEG delta power during the first 30 minutes of recording time. Pre-treatment with the OX2R antagonist prevented this disruption of waking EEG power from occurring. Although measures of NREM and REM sleep were not returned to control levels, the partial mitigation of fentanyl-induced sleep disruption by the OX2R antagonist indicates the orexin system as a viable target for addressing the destructive cycle of poor sleep created and perpetuated by opioid treatment.
Subjects
Degree
Master of Arts
Major
Experimental Psychology
Embargo Date
August 1, 2029